摘要
随着恶性肿瘤治疗的不断发展,免疫检查点抑制剂已应用于多种恶性肿瘤的治疗,使患者的生存时间和生活质量有所改善,但在应用的过程中不可避免地发生免疫相关不良反应。与化疗药物和靶向药物相同,免疫抑制剂也会引起心血管事件,从而影响肿瘤患者的死亡率。随着肿瘤患者生存时间的延长,会日益成为影响这类疾病预后的关键因素。文章重点论述免疫检查点抑制剂在肿瘤治疗过程中引起的心脏毒性机制、临床表现以及未来发展方向。
With the continuous development of cancer treatment,the immune checkpoint inhibitors have been applied to the treatment of a variety of malignant tumors,which improved the patient′s survival time and quality of life.However,immune-related adverse reactions occur inevitably.Like chemotherapeutics and targeted drugs,immunosuppressants can also cause cardiovascular events that affect the mortality of cancer patients.With the extension of the survival time of cancer patients,it will increasingly become a key factor which affects the prognoses of these diseases.This review focuses on the cardiotoxic mechanism,clinical manifestation,and future direction of immune checkpoint inhibitors during cancer treatment.
作者
王文娴
宋正波
张沂平
Wang Wenxian;Song Zhengbo;Zhang Yiping(Department of Thoracic Medical Oncology,Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital,Institute of Cancer and Basic Medicine,Chinese Academy of Sciences,Hangzhou,310011,China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2020年第7期609-613,共5页
Chinese Journal of Oncology
基金
浙江省医药卫生科技计划项目(2017KY250)
浙江省医药卫生科技计划项目(2018KY023)。
